INNO-220

• Description:

  INNO-220 is an orally active, CRBN-dependent molecular glue degrader targeting CK1α. INNO-220 induces cell cycle arrest at G0/G1 phase and triggers apoptosis by degrading CK1α. INNO-220 disrupts the assembly and function of the CARD11/BCL10/MALT1 complex, thereby inhibiting NF-κB signaling in stimulated T cells and lymphoma cells that harbor an activating mutation in CARD11. INNO-220 provides a new direction for lymphoma research[1].

• UNSPSC:

  12352005

• Target:

  Casein Kinase; MALT1; MDM-2/p53; Molecular Glues

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; NF-κB; PROTAC; Stem Cell/Wnt

• Field of Research:

  Cancer

• Purity:

  98.60

• Solubility:

  DMSO : 2.5 mg/mL (ultrasonic)

• Smiles:

  CN1N=CC(C2=CC3=C(C(N(C3)C4CCC(NC4=O)=O)=O)C=C2)=C1C5=CC=CC=C5

• Molecular Formula:

  C23H20N4O3

• Molecular Weight:

  400.43

• References & Citations:

  [1]Shi Feng, et al. A highly selective and orally bioavailable casein kinase 1 alpha degrader through p53 signaling pathway targets B-cell lymphoma cells. Leukemia. 2025 May 27.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [3032576-92-1]